Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06314698 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease

StatusNot Yet Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 18, 2024 (before its estimated December 31, 2024 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
RenJi Hospital
190 trials monitored
See 2 trials at risk
Multiple Myeloma
1,261 trials monitored
See 80 trials at risk
The purpose of this study is to determine if narlumosbart is non-inferior to denosumab in the treatment of bone diseases from multiple myeloma (MM).
Trial Details
NCT Number NCT06314698
Lead Sponsor RenJi Hospital
Collaborators: Shanghai JMT-Bio Inc.
Conditions
(from sponsor)		 Multiple Myeloma, Bone Diseases
Related terms Bone Diseases, Multiple Myeloma
Enrollment 478 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov